Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1127

1.

Amikacin initial dose in critically ill patients: a nonparametric approach to optimize a priori PK/PD target attainments in individual patients.

Boidin C, Bourguignon L, Cohen S, Roger C, Lefrant JY, Roberts JA, Allaouchiche B, Lepape A, Friggeri A, Goutelle S.

Antimicrob Agents Chemother. 2019 Sep 3. pii: AAC.00993-19. doi: 10.1128/AAC.00993-19. [Epub ahead of print]

PMID:
31481443
2.

Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.

Richter DC, Frey O, Röhr A, Roberts JA, Köberer A, Fuchs T, Papadimas N, Heinzel-Gutenbrunner M, Brenner T, Lichtenstern C, Weigand MA, Brinkmann A.

Infection. 2019 Aug 31. doi: 10.1007/s15010-019-01352-z. [Epub ahead of print]

PMID:
31473974
3.

Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.

Kanji S, Roberts JA, Xie J, Zelenitsky S, Hiremath S, Zhang G, Watpool I, Porteous R, Patel R.

Clin Pharmacokinet. 2019 Aug 31. doi: 10.1007/s40262-019-00817-6. [Epub ahead of print]

PMID:
31471789
4.

Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery.

Gurunathan U, Parker SL, Maguire R, Ramdath D, Bijoor M, Wallis SC, Roberts JA.

Anesth Analg. 2019 Sep;129(3):701-708. doi: 10.1213/ANE.0000000000003377.

PMID:
31425209
5.

Corrigendum to "Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients". [Int J Antimicrob Agents 51 (2018) 594-600].

Dhaese SAM, Roberts JA, Carlier M, Verstraete AG, Stove V, De Waele JJ.

Int J Antimicrob Agents. 2019 Sep;54(3):380. doi: 10.1016/j.ijantimicag.2019.07.022. Epub 2019 Aug 6. No abstract available.

PMID:
31399316
6.

Population pharmacokinetics of unbound ceftolozane and tazobactam in critically ill patients without renal dysfunction.

Sime FB, Lassig-Smith M, Starr T, Stuart J, Pandey S, Parker SL, Wallis SC, Lipman J, Roberts JA.

Antimicrob Agents Chemother. 2019 Jul 29. pii: AAC.01265-19. doi: 10.1128/AAC.01265-19. [Epub ahead of print]

7.

What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Sumi CD, Heffernan AJ, Lipman J, Roberts JA, Sime FB.

Clin Pharmacokinet. 2019 Jul 20. doi: 10.1007/s40262-019-00791-z. [Epub ahead of print] Review.

PMID:
31325141
8.

Antimicrobial therapy during ECMO - customised dosing with therapeutic drug monitoring: The way to go?

Abdul-Aziz MH, Shekar K, Roberts JA.

Anaesth Crit Care Pain Med. 2019 Jul 16. pii: S2352-5568(19)30296-6. doi: 10.1016/j.accpm.2019.07.005. [Epub ahead of print] No abstract available.

PMID:
31323318
9.

Corrigendum to 'Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients' [International Journal of Antimicrobial Agents 51 (2018) 594-600].

Dhaese SAM, Roberts JA, Carlier M, Verstraete AG, Stove V, DeWaele JJ.

Int J Antimicrob Agents. 2019 Aug;54(2):271. doi: 10.1016/j.ijantimicag.2019.07.007. Epub 2019 Jul 8. No abstract available.

PMID:
31296408
10.

Population pharmacokinetics of ticarcillin in critically ill patients receiving extended daily diafiltration.

Economou CJP, Xie J, Comadira G, Richards B, Tallott M, Wallis SC, Ordoñez J, Lipman J, Roberts JA.

Int J Antimicrob Agents. 2019 Sep;54(3):351-355. doi: 10.1016/j.ijantimicag.2019.06.027. Epub 2019 Jul 4.

PMID:
31279852
11.

Linezolid dosing in patients with liver cirrhosis: Standard dosing risks toxicity.

Luque S, Muñoz-Bermudez R, Echeverría-Esnal D, Sorli L, Campillo N, Martínez-Casanova J, González-Colominas E, Álvarez-Lerma F, Horcajada JP, Grau S, Roberts JA.

Ther Drug Monit. 2019 Jun 26. doi: 10.1097/FTD.0000000000000665. [Epub ahead of print]

PMID:
31259884
12.

Pharmacokinetics of enteric coated mycophenolate sodium in lupus nephritis (POEMSLUN).

Ranganathan D, Abdul-Aziz MH, John GT, McWhinney BC, Fassett RG, Healy H, Kubler P, Lim A, Lipman J, Purvey M, Roberts M, Reyaldeen R, Ungerer J, Roberts JA.

Ther Drug Monit. 2019 Jun 18. doi: 10.1097/FTD.0000000000000658. [Epub ahead of print]

PMID:
31219949
13.

Large-scale brain modes reorganize between infant sleep states and carry prognostic information for preterms.

Tokariev A, Roberts JA, Zalesky A, Zhao X, Vanhatalo S, Breakspear M, Cocchi L.

Nat Commun. 2019 Jun 13;10(1):2619. doi: 10.1038/s41467-019-10467-8.

14.

Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.

Hagel S, Fiedler S, Hohn A, Brinkmann A, Frey OR, Hoyer H, Schlattmann P, Kiehntopf M, Roberts JA, Pletz MW; TARGET Study Group.

Trials. 2019 Jun 6;20(1):330. doi: 10.1186/s13063-019-3437-x.

15.

Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients.

Sime FB, Byrne CJ, Parker S, Stuart J, Butler J, Starr T, Pandey S, Wallis SC, Lipman J, Roberts JA.

Crit Care. 2019 Jun 6;23(1):205. doi: 10.1186/s13054-019-2483-9.

16.

Pharmacokinetics of Benzylpenicillin (Penicillin G) during Prolonged Intermittent Renal Replacement Therapy.

Cheng V, Rawlins M, Chang T, Fox E, Dyer J, Allen C, Litton E, Page MM, Hoad K, Roberts JA.

Chemotherapy. 2019;64(1):17-21. doi: 10.1159/000499375. Epub 2019 Jun 5.

PMID:
31167190
17.

Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?

Heffernan AJ, Germano A, Sime FB, Roberts JA, Kimura E.

Eur J Clin Pharmacol. 2019 Sep;75(9):1219-1226. doi: 10.1007/s00228-019-02694-1. Epub 2019 Jun 1.

PMID:
31154476
18.

Antibiotic exposure at the site of infection: principles and assessment of tissue penetration.

Jager NGL, van Hest RM, Lipman J, Roberts JA, Cotta MO.

Expert Rev Clin Pharmacol. 2019 Jul;12(7):623-634. doi: 10.1080/17512433.2019.1621161. Epub 2019 May 28. Review.

PMID:
31136211
19.

Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model.

Dhanani JA, Diab S, Chaudhary J, Cohen J, Parker SL, Wallis SC, Boidin C, Barnett A, Chew M, Roberts JA, Fraser JF.

Anesthesiology. 2019 Aug;131(2):344-355. doi: 10.1097/ALN.0000000000002752.

PMID:
31107274
20.

Interferon-Gamma test for the detection of Mycobacterium tuberculosis complex infection in Macaca mulatta and other non-human primates.

Yee JL, Prongay K, Miles B, Smedley J, Hansen SG, Axthelm MK, Ardeshir A, Van Rompay KKA, Timmel G, Roberts JA.

J Med Primatol. 2019 Aug;48(4):260-263. doi: 10.1111/jmp.12420. Epub 2019 May 6.

PMID:
31056769
21.

Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study.

Dhaese SAM, Thooft ADJ, Farkas A, Lipman J, Verstraete AG, Stove V, Roberts JA, De Waele JJ.

J Crit Care. 2019 Aug;52:75-79. doi: 10.1016/j.jcrc.2019.04.013. Epub 2019 Apr 9.

PMID:
30986758
22.

Tunable Hyperbolic Metamaterials Based on Self-Assembled Carbon Nanotubes.

Roberts JA, Yu SJ, Ho PH, Schoeche S, Falk AL, Fan JA.

Nano Lett. 2019 May 8;19(5):3131-3137. doi: 10.1021/acs.nanolett.9b00552. Epub 2019 Apr 10.

PMID:
30950280
23.

In-vitro adsorption and sieving coefficient of ticarcillin-clavulanate during continuous haemofiltration.

T P Wan W, Guerra Valero Y, Choi GYS, Ordóñez Mejia JL, Wallis SC, Joynt GM, Lipman J, Gomersall CD, Roberts JA.

Int J Antimicrob Agents. 2019 Aug;54(2):261-264. doi: 10.1016/j.ijantimicag.2019.03.018. Epub 2019 Mar 21.

PMID:
30904466
24.

Effect of plasmapheresis on ATG (Thymoglobulin) clearance prior to adoptive T cell transfer.

Zhang P, Curley CI, Mudie K, Nakagaki M, Hill GR, Roberts JA, Tey SK.

Bone Marrow Transplant. 2019 Mar 19. doi: 10.1038/s41409-019-0505-5. [Epub ahead of print]

PMID:
30890771
25.

Analysis of capillary microsamples obtained from a skin-prick to measure vancomycin concentrations as a valid alternative to conventional sampling: A bridging study.

Guerra Valero YC, Roberts JA, Lipman J, Fourie C, Starr T, Wallis SC, Parker SL.

J Pharm Biomed Anal. 2019 May 30;169:288-292. doi: 10.1016/j.jpba.2019.03.018. Epub 2019 Mar 9.

PMID:
30889434
26.

Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia.

Weber N, Jackson K, McWhinney B, Ungerer J, Kennedy G, Lipman J, Roberts JA.

J Infect Chemother. 2019 Jul;25(7):503-508. doi: 10.1016/j.jiac.2019.02.014. Epub 2019 Mar 15.

PMID:
30879981
27.

Augmented renal clearance: A real phenomenon with an uncertain cause.

Baptista JP, Roberts JA, Udy AA.

Anaesth Crit Care Pain Med. 2019 Aug;38(4):335-336. doi: 10.1016/j.accpm.2019.03.002. Epub 2019 Mar 9. No abstract available.

PMID:
30857924
28.

A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.

Lipman J, Brett SJ, De Waele JJ, Cotta MO, Davis JS, Finfer S, Glass P, Knowles S, McGuinness S, Myburgh J, Paterson DL, Peake S, Rajbhandari D, Rhodes A, Roberts JA, Shirwadkar C, Starr T, Taylor C, Billot L, Dulhunty JM.

Crit Care Resusc. 2019 Mar;21(1):63-68.

PMID:
30857514
29.

Metastable brain waves.

Roberts JA, Gollo LL, Abeysuriya RG, Roberts G, Mitchell PB, Woolrich MW, Breakspear M.

Nat Commun. 2019 Mar 5;10(1):1056. doi: 10.1038/s41467-019-08999-0.

30.

Multidrug-resistant Acinetobacter baumannii infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation.

Mohd Sazlly Lim S, Sime FB, Roberts JA.

Int J Antimicrob Agents. 2019 Jun;53(6):726-745. doi: 10.1016/j.ijantimicag.2019.02.016. Epub 2019 Mar 2.

PMID:
30831234
31.

Defining optimal dosing of ciprofloxacin in patients with septic shock.

Roberts JA, Alobaid AS, Wallis SC, Perner A, Lipman J, Sjövall F.

J Antimicrob Chemother. 2019 Jun 1;74(6):1662-1669. doi: 10.1093/jac/dkz069.

PMID:
30809648
32.

Development of frontoparietal connectivity predicts longitudinal symptom changes in young people with autism spectrum disorder.

Lin HY, Perry A, Cocchi L, Roberts JA, Tseng WI, Breakspear M, Gau SS.

Transl Psychiatry. 2019 Feb 12;9(1):86. doi: 10.1038/s41398-019-0418-5.

33.

Re-evaluation of the ethylene-dependent and -independent pathways in the regulation of floral and organ abscission.

Meir S, Philosoph-Hadas S, Riov J, Tucker ML, Patterson SE, Roberts JA.

J Exp Bot. 2019 Mar 11;70(5):1461-1467. doi: 10.1093/jxb/erz038.

PMID:
30726930
34.

Heart Rate and Heart Rate Variability of Rhesus Macaques (Macaca mulatta) Affected by Left Ventricular Hypertrophy.

Ueda Y, Slabaugh TL, Walker AL, Ontiveros ES, Sosa PM, Reader R, Roberts JA, Stern JA.

Front Vet Sci. 2019 Jan 22;6:1. doi: 10.3389/fvets.2019.00001. eCollection 2019.

35.

Understanding drivers of antibiotic resistance genes in High Arctic soil ecosystems.

McCann CM, Christgen B, Roberts JA, Su JQ, Arnold KE, Gray ND, Zhu YG, Graham DW.

Environ Int. 2019 Apr;125:497-504. doi: 10.1016/j.envint.2019.01.034. Epub 2019 Jan 28.

36.

Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?

Dimopoulos G, Koulenti D, Parker SL, Roberts JA, Arvaniti K, Poulakou G.

Expert Rev Anti Infect Ther. 2019 Mar;17(3):201-210. doi: 10.1080/14787210.2019.1573669. Epub 2019 Feb 4. Review.

PMID:
30668931
37.

Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations.

Colin PJ, Allegaert K, Thomson AH, Touw DJ, Dolton M, de Hoog M, Roberts JA, Adane ED, Yamamoto M, Santos-Buelga D, Martín-Suarez A, Simon N, Taccone FS, Lo YL, Barcia E, Struys MMRF, Eleveld DJ.

Clin Pharmacokinet. 2019 Jun;58(6):767-780. doi: 10.1007/s40262-018-0727-5.

38.

Solid nanoparticles for oral antimicrobial drug delivery: a review.

Raza A, Sime FB, Cabot PJ, Maqbool F, Roberts JA, Falconer JR.

Drug Discov Today. 2019 Mar;24(3):858-866. doi: 10.1016/j.drudis.2019.01.004. Epub 2019 Jan 14. Review.

PMID:
30654055
39.

Personalized antibiotic dosing for the critically ill.

Roberts JA, Roger C, De Waele JJ.

Intensive Care Med. 2019 May;45(5):715-718. doi: 10.1007/s00134-019-05522-3. Epub 2019 Jan 14. No abstract available.

PMID:
30637444
40.

Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes.

Tenorio-Cañamás T, Grau S, Luque S, Fortún J, Liaño F, Roberts JA.

Ther Drug Monit. 2019 Jun;41(3):376-382. doi: 10.1097/FTD.0000000000000595.

PMID:
30633087
41.

Rotavirus is associated with decompensated diarrhea among young rhesus macaques (Macaca mulatta).

Wang KY, Christe KL, Yee J, Roberts JA, Ardeshir A.

Am J Primatol. 2019 Jan;81(1):e22948. doi: 10.1002/ajp.22948. Epub 2019 Jan 8.

PMID:
30620103
42.

Recovery rates of combination antibiotic therapy using in vitro microdialysis simulating in vivo conditions.

Dhanani JA, Parker SL, Lipman J, Wallis SC, Cohen J, Fraser J, Barnett A, Chew M, Roberts JA.

J Pharm Anal. 2018 Dec;8(6):407-412. doi: 10.1016/j.jpha.2018.07.003. Epub 2018 Jul 6.

43.

Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients.

Cheng V, Abdul-Aziz MH, Roberts JA, Shekar K.

Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):103-112. doi: 10.1080/17425255.2019.1563596. Epub 2019 Jan 3. Review.

PMID:
30582435
44.

In vitro removal of anti-infective agents by a novel cytokine adsorbent system.

König C, Röhr AC, Frey OR, Brinkmann A, Roberts JA, Wichmann D, Braune S, Kluge S, Nierhaus A.

Int J Artif Organs. 2019 Feb;42(2):57-64. doi: 10.1177/0391398818812601. Epub 2018 Dec 13.

PMID:
30545255
45.

Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review.

Heffernan AJ, Sime FB, Lipman J, Dhanani J, Andrews K, Ellwood D, Grimwood K, Roberts JA.

Int J Antimicrob Agents. 2019 Mar;53(3):234-245. doi: 10.1016/j.ijantimicag.2018.11.011. Epub 2018 Nov 23.

PMID:
30472292
46.

Diazepam Toxicity Presenting as a Dementia Disorder.

Kurlawala Z, Roberts JA, McMillan JD, Friedland RP.

J Alzheimers Dis. 2018;66(3):935-938. doi: 10.3233/JAD-180745.

PMID:
30400100
47.

Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models.

Dhaese SAM, Farkas A, Colin P, Lipman J, Stove V, Verstraete AG, Roberts JA, De Waele JJ.

J Antimicrob Chemother. 2019 Feb 1;74(2):432-441. doi: 10.1093/jac/dky434.

PMID:
30376103
48.

Understanding the impact of pathophysiological alterations during critical illness on drug pharmacokinetics.

Jamal JA, Roger C, Roberts JA.

Anaesth Crit Care Pain Med. 2018 Dec;37(6):515-517. doi: 10.1016/j.accpm.2018.10.006. Epub 2018 Oct 22. No abstract available.

PMID:
30359771
49.

Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy.

Rawlins M, Cheng V, Raby E, Dyer J, Regli A, Ingram P, McWhinney BC, Ungerer JPJ, Roberts JA.

Chemotherapy. 2018;63(4):203-206. doi: 10.1159/000493196. Epub 2018 Oct 10.

PMID:
30304718
50.

How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients.

Heffernan AJ, Sime FB, Taccone FS, Roberts JA.

Curr Opin Infect Dis. 2018 Dec;31(6):555-565. doi: 10.1097/QCO.0000000000000494.

PMID:
30299354

Supplemental Content

Loading ...
Support Center